KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBITDA: 2015-2025

Historic EBITDA for Medpace Holdings (MEDP) over the last 10 years, with Sep 2025 value amounting to $148.6 million.

  • Medpace Holdings' EBITDA rose 24.44% to $148.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.5 million, marking a year-over-year increase of 22.61%. This contributed to the annual value of $474.7 million for FY2024, which is 31.51% up from last year.
  • Latest data reveals that Medpace Holdings reported EBITDA of $148.6 million as of Q3 2025, which was up 11.65% from $133.1 million recorded in Q2 2025.
  • Medpace Holdings' 5-year EBITDA high stood at $148.6 million for Q3 2025, and its period low was $46.4 million during Q2 2021.
  • Over the past 3 years, Medpace Holdings' median EBITDA value was $112.0 million (recorded in 2024), while the average stood at $112.5 million.
  • Data for Medpace Holdings' EBITDA shows a peak YoY surged of 43.29% (in 2022) over the last 5 years.
  • Medpace Holdings' EBITDA (Quarterly) stood at $59.0 million in 2021, then skyrocketed by 38.04% to $81.5 million in 2022, then grew by 15.02% to $93.7 million in 2023, then soared by 41.37% to $132.5 million in 2024, then climbed by 24.44% to $148.6 million in 2025.
  • Its last three reported values are $148.6 million in Q3 2025, $133.1 million for Q2 2025, and $120.2 million during Q1 2025.